Our Blog

Alterity Therapeutics (ASX:ATH) – treating neurological disease

09 Jul 2019 – Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug candidate PTB434 for use treating Multiple System Atrophy (MSA).


Source: Finance News Network

Share this post